<DOC>
	<DOCNO>NCT00125801</DOCNO>
	<brief_summary>The purpose study see whether injection hydromorphone subcutaneous injection device effective treating breakthrough cancer pain oral morphine .</brief_summary>
	<brief_title>The Pain Pen Breakthrough Cancer Pain</brief_title>
	<detailed_description>Breakthrough pain exacerbation severe pain occur background otherwise control pain . Breakthrough pain common patient advanced cancer . Current medication treat breakthrough pain include oral immediate release opioid formulation recently oral transmucosal fentanyl citrate . The pain pen study randomize control double blind cross-over study compare efficacy oral immediate release morphine subcutaneous hydromorphone , inject call pain pen , breakthrough pain cancer patient . Preliminary experience pain pen suggest rapid time onset pain relief oral formulation .</detailed_description>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Stable cancer pain require equivalent 601000 mg oral morphine/day 14 breakthrough pain episodes/day Patients must able , opinion investigator , fully comply trial requirement Patients give write informed consent Uncontrolled pain Women pregnant , lactate intend become pregnant Cardiopulmonary disease would increase risk opioids Neurologic psychiatric disease would compromise data collection Recently start chemotherapy radiotherapy far would effective lower breakthrough pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>